Eli Lilly's lead in the obesity race has increased. Its recent stock performance says otherwise.
Eli Lilly investors have received some very good news in recent months, with one notable exception regarding the stock's performance.…
Biotechnology and pharmaceuticals
Medicare May Cover Eli Lilly's Zepbound for Sleep Apnea: Health Department Agency
An injectable pen of Zepbound, Eli Lilly's weight loss drug, is on display in New York City on December 11,…
FDA approvals fall in 2024, Transcarent acquires Accolade
Signs are seen outside the Food and Drug Administration (FDA) headquarters in White Oak, Maryland, on August 29, 2020. Andrew…
J&J says lung cancer drugs Rybrevant and Lazcluze prolong survival
Niels Wenstedt | fake images Johnson & Johnson on tuesday said his lung cancer regimen keeps people alive for at…
Innovative biotech stocks have a good chance of breaking out in 2025
The trends may be turning in favor of biotech stocks in 2025 after several years of poor performance, but it…
Danaher had a disappointing 2024. Your path to success next year passes through Wall Street
Life sciences company Danaher certainly hasn't been an easy stock to buy this year. A wave of new companies going…
Eli Lilly seeks to extend its winning streak in the general market to 6 years
Eli Lilly has outperformed the S&P 500 for five straight years as Wall Street realized its huge opportunity in obesity…
FDA Approves Eli Lilly's Zepbound Weight-Loss Drug for Sleep Apnea
An Eli Lilly & Co. Zepbound injection pen placed in the Brooklyn borough of New York, U.S., on Thursday, March…
Merck signs weight loss pills licensing agreement with Hansoh Pharma
Exterior view of the entrance to Merck headquarters on February 5, 2024 in Rahway, New Jersey. Spencer Platt | fake…
Eli Lilly's Zepbound Weight Loss Drug No Longer in Shortage
An injectable pen of Zepbound, Eli Lilly's weight loss drug, is on display in New York City on December 11,…